成大生物：公司尚未实施本次股份回购

Group 1 - The core point of the article is that Chengda Biological has announced the progress of its share repurchase plan, stating that as of July 31, 2025, the company has not yet implemented this plan and will decide on the timing based on market conditions [2] - For the year 2024, Chengda Biological's revenue composition is entirely from biopharmaceuticals, accounting for 100.0% [2]